A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

How long can you have acute myelogenous leukemia without knowing? AML can develop quickly, with symptoms appearing over a few weeks. On average, people may have symptoms for about 4-6 weeks before ...

Aberrant DNA methylation patterns are a characteristic feature of cancer including myeloid malignancies such as acute myeloid leukemia (AML). The mechanisms behind aberrant DNA methylation have ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

An international clinical trial co-led by Roswell Park Comprehensive Cancer Center has demonstrated that the investigational drug ziftomenib can produce deep, durable responses in people with a ...

Sixteen years later, I heard a doctor say, "We think you have leukemia, but it is not the same kind as your son." I suppose that was meant to comfort me. I was diagnosed with acute myelogenous ...

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid ...

But when these symptoms cluster together, they could be pointing to something far more serious than stress or aging – acute myelogenous leukemia, a rapidly progressing blood cancer that strikes ...

Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).